Compare ONTO & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONTO | PODD |
|---|---|---|
| Founded | 1940 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 10.3B |
| IPO Year | 1995 | 2007 |
| Metric | ONTO | PODD |
|---|---|---|
| Price | $274.80 | $146.37 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 21 |
| Target Price | $290.63 | ★ $341.48 |
| AVG Volume (30 Days) | 1.1M | ★ 1.6M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.67 | ★ 1.30 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | $26.63 | $24.55 |
| Revenue Next Year | $16.26 | $19.18 |
| P/E Ratio | $417.88 | ★ $110.23 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $89.40 | $140.63 |
| 52 Week High | $316.00 | $354.88 |
| Indicator | ONTO | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 38.39 |
| Support Level | $274.97 | $143.11 |
| Resistance Level | $312.85 | $205.95 |
| Average True Range (ATR) | 13.51 | 5.77 |
| MACD | 0.49 | 1.23 |
| Stochastic Oscillator | 87.28 | 36.83 |
Onto Innovation Inc is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the sources of total revenue.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.